NCT06580873View on ClinicalTrials.gov

Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

October 31, 2027

Conditions
HIV-1-infectionOpioid Use Disorder
Interventions
DRUG

DOVATO

HIV-1 medication

Trial Locations (1)

S4P 0W5

Saskatchewan Health Authority, Regina

Sponsors

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Saskatchewan Health Authority - Regina Area

OTHER

NCT06580873 - Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT) | Biotech Hunter | Biotech Hunter